Lifeward Ltd Stock Price, News & Analysis

Lifeward (Nasdaq: LFWD) and MYOLYN have expanded their exclusive partnership to enhance patient access to the MyoCycle FES Cycling Therapy System for home use. The expanded agreement allows Lifeward to manage referrals and sales of MyoCycle Home products for patients transitioning from clinical to home use.

MyoCycle is a stationary exercise bike with integrated electrical stimulation designed for individuals with muscle weakness or paralysis due to conditions like spinal cord injury, multiple sclerosis, and stroke. Previously, Lifeward managed hospital and clinic-based sales of MyoCycle Pro nationwide, as well as home use sales for VA and Workers' Compensation beneficiaries.

Under the new arrangement, MYOLYN will continue directly servicing patients already discharged from therapy. Lifeward has established the necessary case management infrastructure to support anticipated growth in the MyoCycle product line, leveraging shared resources between MyoCycle and ReWalk Exoskeleton.

Lifeward (Nasdaq: LFWD), a global leader in medical technology for people with physical limitations or disabilities, has scheduled its Q4 and fiscal year-end 2024 financial results announcement for March 7, 2025, before market open.

CEO Larry Jasinski and CFO Mike Lawless will host a conference call and live webcast at 8:30 a.m. EST to discuss the results. The webcast will be accessible through the company's website at GoLifeward.com in the Investors section and will also be archived for future viewing.

Lifeward (NASDAQ: LFWD) announced CEO Larry Jasinski's retirement after 13 years of service, with his departure planned for Q2 2025. The board has formed a special committee to search for a successor, considering both internal and external candidates.

The company provided preliminary financial results for 2024, expecting revenue of $25.7 million, within their guidance of $25-26 million. Annual GAAP operating expenses are anticipated at $33.4 million, including $5.7 million in restructuring and impairment expenses. These figures are unaudited and subject to adjustment.

Due to the CEO transition, Lifeward has postponed its February 20th virtual investor event until later in 2025. The company will announce its 2025 financial outlook during its Q4 and full-year 2024 results call, scheduled for the week of March 10, 2025.

Lifeward (NASDAQ: LFWD) has finalized a reimbursement agreement with BARMER, Germany's second-largest statutory health insurer, for ReWalk Personal Exoskeletons. The agreement covers 8.5 million beneficiaries and formalizes the reimbursement process for medically eligible individuals.

BARMER has already provided 20 ReWalk Personal Exoskeletons to beneficiaries, leading Germany in exoskeleton coverage. This agreement means approximately 45% of people with Statutory Health Insurance in Germany now have coverage policies with defined reimbursement processes for personal exoskeletons.

This development follows recent expansion in reimbursement policies, including Medicare coverage in the U.S. and state coverage in Hungary. Lifeward is positioning itself for further expansion through submissions to Medicare Advantage Programs and other U.S. commercial payers.

Lifeward (Nasdaq: LFWD) has announced a virtual Investor Event scheduled for February 20, 2025, at 10:00 am EST. The event will feature presentations and Q&A sessions with executive leadership focusing on the company's strategy, key initiatives, and financial outlook.

The event will showcase innovative products from Lifeward's portfolio, including the ReWalk Exoskeleton for spinal cord injuries and the AlterG Anti-Gravity System for rehabilitation of orthopedic and neurological conditions. The virtual event will be accessible to investors, analysts, media, and other interested parties through a webcast, with both live access and replay available on the Investor Relations section of the Lifeward website at GoLifeward.com.

Lifeward (NASDAQ: LFWD) released a year-end letter highlighting key achievements in 2024 and outlining 2025 objectives. Major 2024 accomplishments include: establishing an Exoskeleton category with CMS for Medicare payment, delivering over 70 new ReWalk systems (double from previous year), building a pipeline of 100 qualified users, and successfully launching NEO and NEO+ additions to the AlterG product line.

The company raised $5 million in early January 2025 to support continued growth. Key 2025 priorities include maximizing exoskeleton execution, expanding AlterG penetration, and completing FDA and CE clearance for ReWalk 7 in H1 2025. The company aims to achieve non-GAAP operating profitability in H2 2026.

Lifeward (Nasdaq: LFWD) has cancelled its Extraordinary General Meeting of Shareholders that was scheduled for January 13, 2025. The company's Board of Directors has withdrawn the proposals outlined in their Definitive Proxy Statement, which was filed with the SEC on November 25, 2024. The Board plans to present these proposals at a future meeting later in 2025.

Lifeward (Nasdaq: LFWD) has announced the closing of a $5 million registered direct offering priced at-the-market under Nasdaq rules. The company issued 1,818,183 ordinary shares at $2.75 per share, along with unregistered warrants to purchase an equal number of shares in a concurrent private placement. The warrants have a three-year term, are immediately exercisable at $2.75 per share.

H.C. Wainwright & Co. served as the exclusive placement agent. The company plans to use the net proceeds for continuing commercial efforts, working capital, and general corporate purposes. The offering was conducted under a previously filed S-3 shelf registration statement, while the warrants were issued privately under Section 4(a)(2) of the Securities Act.

Lifeward (Nasdaq: LFWD) has announced a $5 million registered direct offering priced at-the-market under Nasdaq rules. The company will issue 1,818,183 ordinary shares at $2.75 per share, along with a concurrent private placement of unregistered warrants to purchase an equal number of ordinary shares.

The warrants will have a three-year term, be immediately exercisable at $2.75 per share. H.C. Wainwright & Co. is serving as the exclusive placement agent. The offering is expected to close around January 8, 2025.

The company plans to use the net proceeds for continuing commercial efforts, working capital, and general corporate purposes. The ordinary shares are being offered under a previously filed S-3 shelf registration, while the warrants are being issued through a private placement under Section 4(a)(2) of the Securities Act.